These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 7040708)

  • 1. Influence of subsalicylate bismuth on absorption of doxycycline.
    Ericsson CD; Feldman S; Pickering LK; Cleary TG
    JAMA; 1982 Apr; 247(16):2266-7. PubMed ID: 7040708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of bismuth subsalicylate on ciprofloxacin bioavailability.
    Rambout L; Sahai J; Gallicano K; Oliveras L; Garber G
    Antimicrob Agents Chemother; 1994 Sep; 38(9):2187-90. PubMed ID: 7811043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced tetracycline bioavailability caused by magnesium aluminum silicate in liquid formulations of bismuth subsalicylate.
    Healy DP; Dansereau RJ; Dunn AB; Clendening CE; Mounts AW; Deepe GS
    Ann Pharmacother; 1997 Dec; 31(12):1460-4. PubMed ID: 9416381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Bismuth Subsalicylate on Gastrointestinal Tolerability in Healthy Volunteers Receiving Oral Delayed-release Dimethyl Fumarate: PREVENT, a Randomized, Multicenter, Double-blind, Placebo-controlled Study.
    Koulinska I; Riester K; Chalkias S; Edwards MR
    Clin Ther; 2018 Dec; 40(12):2021-2030.e1. PubMed ID: 30447891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind comparison of bismuth subsalicylate and placebo in the prevention and treatment of enterotoxigenic Escherichia coli-induced diarrhea in volunteers.
    Graham DY; Estes MK; Gentry LO
    Gastroenterology; 1983 Nov; 85(5):1017-22. PubMed ID: 6352386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of bismuth subsalicylate with fruit juices, ascorbic acid, and thiol-containing substrates to produce soluble bismuth products active against Clostridium difficile.
    Mahony DE; Woods A; Eelman MD; Burford N; Veldhuyzen van Zanten SJ
    Antimicrob Agents Chemother; 2005 Jan; 49(1):431-3. PubMed ID: 15616328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of travelers' diarrhea by the tablet formulation of bismuth subsalicylate.
    DuPont HL; Ericsson CD; Johnson PC; Bitsura JA; DuPont MW; de la Cabada FJ
    JAMA; 1987 Mar; 257(10):1347-50. PubMed ID: 3820443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro bile acid adsorption by bismuth subsalicylate and montmorillonite.
    Kocoshis SA; Ghent CN; Gryboski JD
    Dig Dis Sci; 1984 Dec; 29(12):1148-52. PubMed ID: 6499633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy of loperamide hydrochloride and bismuth subsalicylate in the management of acute diarrhea.
    DuPont HL; Flores Sanchez J; Ericsson CD; Mendiola Gomez J; DuPont MW; Cruz Luna A; Mathewson JJ
    Am J Med; 1990 Jun; 88(6A):15S-19S. PubMed ID: 2192553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology of bismuth-containing compounds.
    Lambert JR
    Rev Infect Dis; 1991; 13 Suppl 8():S691-5. PubMed ID: 1925310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absorption of salicylate and bismuth from a bismuth subsalicylate--containing compound (Pepto-Bismol).
    Pickering LK; Feldman S; Ericsson CD; Cleary TG
    J Pediatr; 1981 Oct; 99(4):654-6. PubMed ID: 7277115
    [No Abstract]   [Full Text] [Related]  

  • 12. Decreased tetracycline bioavailability caused by a bismuth subsalicylate antidiarrheal mixture.
    Albert KS; Welch RD; DeSante KA; DiSanto AR
    J Pharm Sci; 1979 May; 68(5):586-8. PubMed ID: 435335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of loperamide with bismuth subsalicylate for the treatment of acute travelers' diarrhea.
    Johnson PC; Ericsson CD; DuPont HL; Morgan DR; Bitsura JA; Wood LV
    JAMA; 1986 Feb; 255(6):757-60. PubMed ID: 3944976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of diarrhea caused by enterotoxigenic Escherichia coli: lessons learned with volunteers.
    Graham DY; Evans DG
    Rev Infect Dis; 1990; 12 Suppl 1():S68-72. PubMed ID: 2406859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence that bismuth salts reduce invasion of epithelial cells by enteroinvasive bacteria.
    Gump DW; Nadeau OW; Hendricks GM; Meyer DH
    Med Microbiol Immunol; 1992; 181(3):131-43. PubMed ID: 1522823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salicylate absorption from a bismuth subsalicylate preparation.
    Feldman S; Chen SL; Pickering LK; Cleary TG; Ericsson CD; Hulse M
    Clin Pharmacol Ther; 1981 Jun; 29(6):788-92. PubMed ID: 7226711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of bismuth subsalicylate in relieving symptoms of indigestion.
    Hailey FJ; Newsom JH
    Arch Intern Med; 1984 Feb; 144(2):269-72. PubMed ID: 6365007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytoprotective effect of bismuth subsalicylate in indomethacin-treated rats is associated with enhanced mucus bismuth concentration.
    Tanaka S; Guth PH; Carryl OR; Kaunitz JD
    Aliment Pharmacol Ther; 1997 Jun; 11(3):605-12. PubMed ID: 9218090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bismuth subsalicylate in the treatment of chronic diarrhea of childhood.
    Gryboski JD; Hillemeier AC; Grill B; Kocoshis S
    Am J Gastroenterol; 1985 Nov; 80(11):871-6. PubMed ID: 3901731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bismuth subsalicylate: history, chemistry, and safety.
    Bierer DW
    Rev Infect Dis; 1990; 12 Suppl 1():S3-8. PubMed ID: 2406853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.